SGLT2 inhibitors work by blocking a protein in your kidneys that normally recaptures glucose from urine and sends it back into your bloodstream. With that protein blocked, excess glucose passes out of your body when you urinate, lowering blood sugar without relying on insulin. This simple mechanism triggers a cascade of secondary effects that benefit blood pressure, body weight, the heart, and the kidneys themselves.
What Happens Inside the Kidney
Your kidneys filter about 180 grams of glucose from your blood every day. Under normal conditions, roughly 97% of that glucose gets reabsorbed in the earliest stretch of the kidney’s tiny filtering tubes, called the proximal tubule. A transporter protein called SGLT2 does the heavy lifting here, pulling glucose (along with sodium) out of the fluid destined to become urine and shuttling it back into the bloodstream.
When you take an SGLT2 inhibitor, that transporter is blocked. Some glucose shifts to a backup transporter further downstream, but a substantial portion simply stays in the urine. In practice, this means you excrete somewhere between 50 and 80 grams of glucose per day, which translates to roughly 200 to 320 extra calories lost daily. The body can’t fully compensate: blood sugar drops, and over months, HbA1c (a marker of average blood sugar) typically falls by 0.5% to 1.0%.
Effects on Blood Pressure and Weight
Because SGLT2 moves sodium alongside glucose, blocking it also increases the amount of sodium leaving your body. More sodium in the urine pulls water with it, producing a mild diuretic effect. That fluid shift helps lower blood pressure, which is one reason these drugs appeal to people managing both diabetes and hypertension.
Weight loss follows two pathways. Early on, losing extra fluid accounts for part of the drop on the scale. Over time, the bigger driver is calorie loss: your body compensates for the glucose it’s excreting by breaking down fat stores. A meta-analysis of 43 randomized trials found that people taking SGLT2 inhibitors lost an average of 1.88 kg (about 4 pounds) more than those on placebo. That number is modest, but it comes essentially for free on top of the blood sugar benefit.
How They Protect the Kidneys
One of the most important effects of SGLT2 inhibitors has nothing to do with glucose. By increasing sodium delivery to a sensor downstream in the kidney (a structure called the macula densa), these drugs reset a feedback loop that controls pressure inside the kidney’s filtering units, the glomeruli. The result is lower pressure in those delicate structures, which slows the kind of damage that leads to progressive kidney disease.
The exact mechanism is still debated. The classic explanation is that the feedback loop constricts the blood vessel entering the glomerulus, reducing the force of blood pushing through the filter. But at least one study using precise blood-flow measurements found the opposite: pressure dropped because the blood vessel leaving the glomerulus relaxed instead, particularly in people already taking common blood pressure medications that act on the same outflow vessel. Either way, the net effect is the same. Filtration pressure falls, and the kidney is spared from overwork. Current guidelines allow doctors to start these drugs in patients with kidney function as low as an eGFR of 20, a threshold that was lowered from 30 in 2022 to extend protection to more people with chronic kidney disease.
Why They Help the Heart
SGLT2 inhibitors reduce the risk of hospitalization for heart failure, and this benefit holds even in people who don’t have diabetes. Several mechanisms likely contribute. The mild but sustained fluid loss reduces blood volume, easing the workload on a struggling heart. Less sodium retention means less fluid congestion in the lungs and legs.
Beyond fluid balance, losing glucose in the urine shifts the body’s fuel mix. When less glucose is available, the heart and other organs rely more on ketone bodies and fatty acids for energy. Ketones are a particularly efficient fuel for heart muscle, and some researchers believe this metabolic shift helps a failing heart work more effectively with less oxygen. The drugs also lower body weight and blood pressure over time, both of which reduce cardiac strain.
Available Medications
Three SGLT2 inhibitors are widely prescribed: canagliflozin (brand name Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance). Each is available on its own or combined with metformin in a single pill. All three share the same core mechanism, though they differ slightly in potency and in which clinical trials support their use for heart failure or kidney disease specifically. Your prescriber will typically choose based on your particular combination of conditions and insurance coverage.
Side Effects Worth Knowing About
The most common side effect is genital yeast infections, which makes sense: sugar-rich urine creates a welcoming environment for yeast. Urinary tract infections also occur more frequently, though the increase is smaller than many people expect. Staying well hydrated and practicing good hygiene reduces both risks.
A rarer but more serious concern is a condition called euglycemic ketoacidosis. Normally, diabetic ketoacidosis comes with very high blood sugar, which serves as a red flag. SGLT2 inhibitors can mask that signal. Because the drugs flush glucose out through the kidneys, blood sugar may stay below 250 mg/dL even as the body shifts heavily into fat burning and produces dangerous levels of ketones. This happens because the continuous glucose loss mimics a state of carbohydrate starvation: insulin levels fall, glucagon rises, and the liver ramps up ketone production. SGLT2 inhibitors also appear to directly stimulate glucagon release from the pancreas and increase ketone reabsorption in the kidneys, compounding the problem.
Triggers for this rare event include surgery, prolonged fasting, heavy alcohol use, and serious infections. The key warning signs are nausea, vomiting, abdominal pain, and unusual fatigue, even when your glucose reading looks normal. If you experience these symptoms while taking an SGLT2 inhibitor, seek medical attention promptly, because standard glucose checks alone won’t catch the problem.
Canagliflozin specifically carries an FDA warning about a small increased risk of toe and foot amputations, mostly in people who already have peripheral vascular disease or a history of amputation. This risk has not been clearly linked to dapagliflozin or empagliflozin.
Why the Mechanism Matters Beyond Blood Sugar
What makes SGLT2 inhibitors unusual in diabetes treatment is that their benefits extend well past glucose control. Most diabetes drugs work by increasing insulin or making cells more sensitive to it. SGLT2 inhibitors bypass insulin entirely. They work as long as the kidneys are filtering blood, regardless of how much insulin your pancreas produces. That insulin-independent action is why they’re now prescribed for heart failure and chronic kidney disease in people who don’t have diabetes at all. The glucose in the urine is almost a side effect of the real therapeutic prize: reduced pressure in the kidneys, less fluid overload on the heart, and a subtle but meaningful shift in how the body fuels itself.